Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 268 articles:
HTML format
Text format



Single Articles


    February 2018
  1. VARI F, Arpon D, Keane C, Hertzberg MS, et al
    Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
    Blood. 2018 Feb 15. pii: blood-2017-07-796342. doi: 10.1182/blood-2017-07-796342
    PubMed     Text format     Abstract available


  2. SPINA V, Bruscaggin A, Cuccaro A, Martini M, et al
    Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma.
    Blood. 2018 Feb 15. pii: blood-2017-11-812073. doi: 10.1182/blood-2017-11-812073
    PubMed     Text format     Abstract available



  3. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
    Blood. 2018;131:587-588.
    PubMed     Text format    


  4. COTTEREAU AS, Versari A, Loft A, Casasnovas O, et al
    Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial.
    Blood. 2018 Feb 1. pii: blood-2017-07-795476. doi: 10.1182/blood-2017-07-795476.
    PubMed     Text format     Abstract available


  5. JIANG W, Zhou X, Li Z, Liu K, et al
    Prolyl 4-Hydroxylase 2 Promotes B-cell Lymphoma Progression via Hydroxylation of Carabin.
    Blood. 2018 Feb 1. pii: blood-2017-07-794875. doi: 10.1182/blood-2017-07-794875.
    PubMed     Text format     Abstract available


    January 2018
  6. VOSE JM
    Peripheral T-cell lymphoma: novel backbone.
    Blood. 2018;131:375-376.
    PubMed     Text format    


    December 2017
  7. BATTISTELLA M, Leboeuf C, Ram-Wolff C, Hurabielle C, et al
    KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.
    Blood. 2017;130:2900-2902.
    PubMed     Text format    


  8. FRIEDBERG JW, Forero-Torres A, Bordoni RE, Cline VJM, et al
    Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL.
    Blood. 2017;130:2829-2837.
    PubMed     Text format     Abstract available


  9. ZINZANI PL
    ALCL: is it now a curable disease?
    Blood. 2017;130:2691-2692.
    PubMed     Text format    


  10. HORWITZ SM, Koch R, Porcu P, Oki Y, et al
    Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.
    Blood. 2017 Dec 12. pii: blood-2017-08-802470. doi: 10.1182/blood-2017-08-802470
    PubMed     Text format     Abstract available


  11. HERRERA AF, Moskowitz AJ, Bartlett NL, Vose JM, et al
    Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2017 Dec 11. pii: blood-2017-10-811224. doi: 10.1182/blood-2017-10-811224
    PubMed     Text format     Abstract available


    November 2017
  12. STEIDL C
    The ecosystem of classical Hodgkin lymphoma.
    Blood. 2017;130:2360-2361.
    PubMed     Text format    


  13. KOHNKEN R, Wen J, Mundy-Bosse B, McConnell K, et al
    Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
    Blood. 2017 Nov 27. pii: blood-2017-09-805663. doi: 10.1182/blood-2017-09-805663
    PubMed     Text format     Abstract available


  14. LIU WR, Shipp MA
    Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Blood. 2017;130:2265-2270.
    PubMed     Text format     Abstract available


  15. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.
    PubMed     Text format    


  16. GREEN MR
    Chromatin modifying gene mutations in follicular lymphoma.
    Blood. 2017 Nov 20. pii: blood-2017-08-737361. doi: 10.1182/blood-2017-08-737361
    PubMed     Text format     Abstract available



  17. Diffuse large B-cell lymphoma in the elderly.
    Blood. 2017;130:2235.
    PubMed     Text format    


  18. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.
    PubMed     Text format    


  19. GALLAMINI A
    Relapsed/refractory HL: FDG-PET is the trump card.
    Blood. 2017;130:2154-2155.
    PubMed     Text format    


  20. AMENGUAL JE, Lichtenstein R, Lue J, Sawas A, et al
    A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Blood. 2017 Nov 15. pii: blood-2017-09-806737. doi: 10.1182/blood-2017-09-806737
    PubMed     Text format     Abstract available


  21. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.
    PubMed     Text format    


  22. MOTTOK A, Jurinovic V, Farinha P, Rosenwald A, et al
    FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens.
    Blood. 2017 Nov 9. pii: blood-2017-08-799080. doi: 10.1182/blood-2017-08-799080.
    PubMed     Text format     Abstract available


  23. RYAN MC, Palanca-Wessels MC, Schimpf B, Gordon KA, et al
    Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
    Blood. 2017;130:2018-2026.
    PubMed     Text format     Abstract available


    October 2017
  24. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available


  25. FISH K, Sora RP, Schaller SJ, Longnecker R, et al
    EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.
    Blood. 2017 Oct 26. pii: blood-2017-07-796821. doi: 10.1182/blood-2017-07-796821
    PubMed     Text format     Abstract available


  26. BARTLETT NL, Costello BA, LaPlant BR, Ansell SM, et al
    Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial.
    Blood. 2017 Oct 26. pii: blood-2017-09-804641. doi: 10.1182/blood-2017-09-804641
    PubMed     Text format     Abstract available


  27. LAMY T, Damaj G, Soubeyran P, Gyan E, et al
    R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL).
    Blood. 2017 Oct 23. pii: blood-2017-07-793984. doi: 10.1182/blood-2017-07-793984
    PubMed     Text format     Abstract available



  28. Genomic analysis of adult Burkitt lymphoma.
    Blood. 2017;130:1871.
    PubMed     Text format    


  29. PILERI SA
    Understanding lymphoma molecular complexity.
    Blood. 2017;130:1780-1781.
    PubMed     Text format    


  30. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.
    PubMed     Text format    


  31. AKHTARI M, Milgrom SA, Pinnix CC, Reddy JP, et al
    Re-classifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.
    Blood. 2017 Oct 16. pii: blood-2017-04-773838. doi: 10.1182/blood-2017-04-773838
    PubMed     Text format     Abstract available


  32. BALAKRISHNA JP, Jaffe ES
    Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma.
    Blood. 2017;130:1683.
    PubMed     Text format    


  33. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Text format     Abstract available


  34. PRO B, Advani R, Brice P, Bartlett NL, et al
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
    Blood. 2017 Oct 3. pii: blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049.
    PubMed     Text format     Abstract available


  35. CYRENNE BM, Lewis J, Weed J, Carlson K, et al
    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood. 2017 Oct 2. pii: blood-2017-06-792150. doi: 10.1182/blood-2017-06-792150.
    PubMed     Text format     Abstract available


    September 2017

  36. MALT lymphoma prognostic index.
    Blood. 2017;130:1486.
    PubMed     Text format    


  37. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.
    PubMed     Text format    


  38. PARK J, Yang J, Wenzel AT, Ramachandran A, et al
    Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).
    Blood. 2017;130:1430-1440.
    PubMed     Text format     Abstract available


  39. MISHRA A, Porcu P
    Expanding and expounding the genomic map of CTCL.
    Blood. 2017;130:1389-1390.
    PubMed     Text format    


  40. ROELENS M, Delord M, Ram-Wolff C, Marie-Cardine A, et al
    Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity.
    Blood. 2017;130:1468-1471.
    PubMed     Text format    


  41. MALEK A, Bhagat G
    Cyclin D1-negative mantle cell lymphoma with aberrant CD3 expression.
    Blood. 2017;130:1388.
    PubMed     Text format    


  42. STEPHENS DM
    Brentuximab: is it time for a new "B" in ABVD?
    Blood. 2017;130:1281-1282.
    PubMed     Text format    


  43. HERTZBERG M
    High-risk DLBCL: interim PET? Not yet.
    Blood. 2017;130:1277-1278.
    PubMed     Text format    


  44. MARTIN P, Ruan J, Leonard JP
    The potential for chemotherapy-free strategies in mantle cell lymphoma.
    Blood. 2017 Sep 12. pii: blood-2017-05-737510. doi: 10.1182/blood-2017-05-737510
    PubMed     Text format     Abstract available


  45. CAREY CD, Gusenleitner D, Lipschitz M, Roemer MGM, et al
    Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Blood. 2017 Sep 11. pii: blood-2017-03-770719. doi: 10.1182/blood-2017-03-770719
    PubMed     Text format     Abstract available


  46. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    


  47. TESSON B, Huet S, Grange B, Jallades L, et al
    Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes.
    Blood. 2017;130:1267-1269.
    PubMed     Text format    


  48. MOSKOWITZ AJ, Schoder H, Gavane S, Thoren KL, et al
    Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
    Blood. 2017 Sep 5. pii: blood-2017-06-788877. doi: 10.1182/blood-2017-06-788877.
    PubMed     Text format     Abstract available


    August 2017
  49. KHODARAHMI I, Ghesani N
    Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
    Blood. 2017;130:1174.
    PubMed     Text format    


  50. DAVIDS MS
    Targeting BCL-2 in B-cell lymphomas.
    Blood. 2017;130:1081-1088.
    PubMed     Text format     Abstract available


  51. KREMER KN, Dinkel BA, Sterner RM, Osborne DG, et al
    TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.
    Blood. 2017;130:982-994.
    PubMed     Text format     Abstract available


  52. ESKELUND CW, Dahl C, Hansen JW, Westman M, et al
    TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
    Blood. 2017 Aug 17. pii: blood-2017-04-779736. doi: 10.1182/blood-2017-04-779736
    PubMed     Text format     Abstract available


  53. LIN RJ, Behera M, Diefenbach CS, Flowers CR, et al
    The Role of Anthracycline and Comprehensive Geriatric Assessment for Elderly Patients with Diffuse Large B-cell Lymphoma.
    Blood. 2017 Aug 16. pii: blood-2017-05-736975. doi: 10.1182/blood-2017-05-736975
    PubMed     Text format    


  54. BOUSKA A, Bi C, Lone W, Zhang W, et al
    Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
    Blood. 2017 Aug 11. pii: blood-2017-02-767335. doi: 10.1182/blood-2017-02-767335
    PubMed     Text format     Abstract available


  55. SALAR A, Domingo-Domenech E, Panizo C, Nicolas C, et al
    Long-term results of a phase II study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
    Blood. 2017 Aug 11. pii: blood-2017-07-795302. doi: 10.1182/blood-2017-07-795302
    PubMed     Text format    


  56. OKONKWO L, Jaffe ES
    Intravascular large cell lymphoma of NK/T-cell type, EBV positive.
    Blood. 2017;130:837.
    PubMed     Text format    


  57. NAM AS, Tam W
    An intrasinusoidal extracavitary variant of primary effusion lymphoma.
    Blood. 2017;130:836.
    PubMed     Text format    


  58. WEIGERT O, Weinstock DM
    The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.
    Blood. 2017 Aug 7. pii: blood-2017-07-737353. doi: 10.1182/blood-2017-07-737353.
    PubMed     Text format     Abstract available


  59. CRUMP M, Neelapu SS, Farooq U, Van Den Neste E, et al
    Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
    Blood. 2017 Aug 3. pii: blood-2017-03-769620. doi: 10.1182/blood-2017-03-769620.
    PubMed     Text format     Abstract available


  60. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Text format     Abstract available


    July 2017
  61. TSUYAMA N, Sakata S, Baba S, Mishima Y, et al
    BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
    Blood. 2017;130:489-500.
    PubMed     Text format     Abstract available


  62. DOMINGUEZ-SOLA D
    SOX11 holds mantle cell lymphoma's key to home.
    Blood. 2017;130:389-391.
    PubMed     Text format    


  63. EICHENAUER DA, Engert A
    R-CHOP in NLPHL: who should receive it?
    Blood. 2017;130:387-388.
    PubMed     Text format    


  64. COURTOIS L, Sujobert P
    Morphologic features of mu-heavy-chain disease.
    Blood. 2017;130:558.
    PubMed     Text format    


  65. CONNORS JM, Ansell SM, Fanale M, Park SI, et al
    Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma.
    Blood. 2017 Jul 21. pii: blood-2017-05-784678. doi: 10.1182/blood-2017-05-784678
    PubMed     Text format    



  66. Predicting transformation of follicular lymphoma.
    Blood. 2017;130:383.
    PubMed     Text format    


  67. GONG S, Hijiya N
    Classical Hodgkin lymphoma and Castleman disease: a rare morphologic combination.
    Blood. 2017;130:381.
    PubMed     Text format    


  68. FEHNIGER TA
    CD70 turns on NK cells to attack lymphoma.
    Blood. 2017;130:238-239.
    PubMed     Text format    


  69. CABANILLAS F, Rivera N
    Check this checkpoint inhibitor in lymphoma.
    Blood. 2017;130:234-235.
    PubMed     Text format    


  70. ERDMANN T, Klener P, Lynch JT, Grau M, et al
    Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Blood. 2017;130:310-322.
    PubMed     Text format     Abstract available


  71. THIEBLEMONT C, Cascione L, Conconi A, Kiesewetter B, et al
    A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial.
    Blood. 2017 Jul 18. pii: blood-2017-03-771915. doi: 10.1182/blood-2017-03-771915
    PubMed     Text format     Abstract available


  72. WOODS DM, Woan KV, Cheng F, Sodre AL, et al
    T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.
    Blood. 2017;130:146-155.
    PubMed     Text format     Abstract available


  73. CASASNOVAS RO, Ysebaert L, Thieblemont C, Bachy E, et al
    A FDG-PET driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase II study.
    Blood. 2017 Jul 12. pii: blood-2017-02-766691. doi: 10.1182/blood-2017-02-766691
    PubMed     Text format     Abstract available


  74. SZYDLOWSKI M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezinska E, et al
    Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Blood. 2017 Jul 11. pii: blood-2017-01-760702. doi: 10.1182/blood-2017-01-760702
    PubMed     Text format     Abstract available


    June 2017
  75. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.
    PubMed     Text format    


  76. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Text format     Abstract available


  77. HAVRANEK O, Xu J, Kohrer S, Wang Z, et al
    Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-10-747303. doi: 10.1182/blood-2016-10-747303
    PubMed     Text format     Abstract available


  78. CHIN CK, Cheah CY
    How I treat patients with aggressive lymphoma at high risk of CNS relapse.
    Blood. 2017 Jun 13. pii: blood-2017-03-737460. doi: 10.1182/blood-2017-03-737460
    PubMed     Text format     Abstract available


  79. FRIEDBERG JW
    How I treat "Double Hit" lymphoma.
    Blood. 2017 Jun 9. pii: blood-2017-04-737320. doi: 10.1182/blood-2017-04-737320.
    PubMed     Text format     Abstract available


  80. CHRISTIAN B
    Checkpoint inhibition in CNS lymphoma.
    Blood. 2017;129:3045-3046.
    PubMed     Text format    


  81. ZHANG H, Chen Z, Miranda RN, Medeiros LJ, et al
    Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.
    Blood. 2017 Jun 7. pii: blood-2017-02-767293. doi: 10.1182/blood-2017-02-767293.
    PubMed     Text format     Abstract available


    May 2017
  82. GILL K
    CD5-negative mantle cell lymphoma of the breast.
    Blood. 2017;129:2950.
    PubMed     Text format    


  83. SCHMIDT J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, et al
    Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.
    Blood. 2017 May 22. pii: blood-2017-03-776278. doi: 10.1182/blood-2017-03-776278
    PubMed     Text format     Abstract available


  84. BALSAS P, Palomero J, Eguileor A, Rodriguez ML, et al
    SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
    Blood. 2017 May 22. pii: blood-2017-04-776740. doi: 10.1182/blood-2017-04-776740
    PubMed     Text format     Abstract available


  85. FANALE MA, Cheah CY, Rich A, Medeiros LJ, et al
    Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Blood. 2017 May 18. pii: blood-2017-02-766121. doi: 10.1182/blood-2017-02-766121
    PubMed     Text format     Abstract available


  86. PEDERSEN MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, et al
    DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.
    Blood. 2017 May 18. pii: blood-2016-12-755496. doi: 10.1182/blood-2016-12-755496
    PubMed     Text format    


  87. GAY C, Delarue R, Milpied N, Oberic L, et al
    Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.
    Blood. 2017;129:2811-2813.
    PubMed     Text format    


  88. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available


  89. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.
    PubMed     Text format    


  90. TOUT M, Casasnovas O, Meignan M, Lamy T, et al
    Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
    Blood. 2017;129:2616-2623.
    PubMed     Text format     Abstract available


  91. ZINZANI PL, Ribrag V, Moskowitz CH, Michot JM, et al
    Safety & tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
    Blood. 2017 May 10. pii: blood-2016-12-758383. doi: 10.1182/blood-2016-12-758383
    PubMed     Text format     Abstract available


  92. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.
    PubMed     Text format    


  93. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.
    PubMed     Text format    


  94. HAVERKOS BM, Abbott D, Hamadani M, Armand P, et al
    PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Blood. 2017 May 3. pii: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346.
    PubMed     Text format     Abstract available


  95. KURUVILLA J, Savona M, Baz R, Mau-Sorensen M, et al
    Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma.
    Blood. 2017 May 3. pii: blood-2016-11-750174. doi: 10.1182/blood-2016-11-750174.
    PubMed     Text format     Abstract available


    April 2017
  96. JACCARD A, Hermine O
    A major turning point in NK/T-cell lymphoma?
    Blood. 2017;129:2342-2343.
    PubMed     Text format    


  97. BUJISIC B, De Gassart A, Tallant R, Demaria O, et al
    Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Blood. 2017;129:2420-2428.
    PubMed     Text format     Abstract available


  98. CHIECCHIO L, Cullis JO
    De novo Richter transformation.
    Blood. 2017;129:2455.
    PubMed     Text format    



  99. Risk of heart failure following Hodgkin lymphoma.
    Blood. 2017;129:2334.
    PubMed     Text format    


  100. BHATT S, Parvin S, Zhang Y, Cho HM, et al
    Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Blood. 2017;129:2246-2256.
    PubMed     Text format     Abstract available


  101. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  102. LE GOUILL S, Casasnovas RO
    Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver?
    Blood. 2017 Apr 17. pii: blood-2016-05-672196. doi: 10.1182/blood-2016-05-672196
    PubMed     Text format     Abstract available


  103. KRIDEL R, Sehn LH, Gascoyne RD
    Can histologic transformation of follicular lymphoma be predicted and prevented?
    Blood. 2017 Apr 13. pii: blood-2017-03-691345. doi: 10.1182/blood-2017-03-691345
    PubMed     Text format     Abstract available


  104. MILLER HK, Santo L, Camargo MC, Winkler CA, et al
    Coxiella burnetii antibody seropositivity is not a risk factor for AIDS-related non-Hodgkin lymphoma.
    Blood. 2017 Apr 10. pii: blood-2016-12-756569. doi: 10.1182/blood-2016-12-756569
    PubMed     Text format    


  105. KAKKASSERY V, Schroers R, Coupland SE, Wunderlich MI, et al
    Vitreous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma.
    Blood. 2017 Apr 7. pii: blood-2017-01-765180. doi: 10.1182/blood-2017-01-765180.
    PubMed     Text format    


    March 2017
  106. KAWASAKI K, Karube K
    Peripheral T-cell lymphoma with EBV-infected "anaplastic" B-cell proliferation confined to sinuses.
    Blood. 2017;129:1885.
    PubMed     Text format    


  107. ALINARI L
    Toward autophagy-targeted therapy in lymphoma.
    Blood. 2017;129:1740-1742.
    PubMed     Text format    


  108. NAYAK L, Iwamoto FM, LaCasce A, Mukundan S, et al
    PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
    Blood. 2017 Mar 29. pii: blood-2017-01-764209. doi: 10.1182/blood-2017-01-764209
    PubMed     Text format     Abstract available


  109. ENNISHI D, Mottok A, Ben-Neriah S, Shulha HP, et al
    Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact.
    Blood. 2017 Mar 28. pii: blood-2016-11-747022. doi: 10.1182/blood-2016-11-747022
    PubMed     Text format     Abstract available


  110. GOPAL AK, Kahl BS, Flowers CR, Martin P, et al
    Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
    Blood. 2017 Mar 21. pii: blood-2016-12-757740. doi: 10.1182/blood-2016-12-757740
    PubMed     Text format    


  111. GARCIA-RAMIREZ I, Tadros S, Gonzalez-Herrero I, Martin-Lorenzo A, et al
    Crebbp loss cooperates with Bcl2 over-expression to promote lymphoma in mice.
    Blood. 2017 Mar 13. pii: blood-2016-08-733469. doi: 10.1182/blood-2016-08-733469
    PubMed     Text format     Abstract available


  112. WANG HY, Thorson JA
    A CD34-negative MYC-rearranged B-lymphoblastic lymphoma aberrantly expresses CD3 and CD5.
    Blood. 2017;129:1403.
    PubMed     Text format    


  113. JAHN L, Hombrink P, Hagedoorn RS, Kester MG, et al
    TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
    Blood. 2017;129:1284-1295.
    PubMed     Text format     Abstract available


  114. HERBAUX C, Gauthier J, Brice P, Drumez E, et al
    Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin's lymphoma.
    Blood. 2017 Mar 7. pii: blood-2016-11-749556. doi: 10.1182/blood-2016-11-749556.
    PubMed     Text format     Abstract available


  115. ZINZANI PL, Pellegrini C, Chiappella A, Di Rocco A, et al
    Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.
    Blood. 2017 Mar 6. pii: blood-2017-01-764258. doi: 10.1182/blood-2017-01-764258.
    PubMed     Text format    


  116. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.
    PubMed     Text format    


    February 2017
  117. CHONG EA, Melenhorst JJ, Lacey SF, Ambrose DE, et al
    PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
    Blood. 2017;129:1039-1041.
    PubMed     Text format    


  118. PANDEY S, Mourcin F, Marchand T, Nayar S, et al
    IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma.
    Blood. 2017 Feb 15. pii: blood-2016-08-737239. doi: 10.1182/blood-2016-08-737239
    PubMed     Text format     Abstract available


  119. KWONG YL, Chan TS, Tan D, Kim SJ, et al
    PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase.
    Blood. 2017 Feb 10. pii: blood-2016-12-756841. doi: 10.1182/blood-2016-12-756841
    PubMed     Text format     Abstract available


  120. BARTOLOME-IZQUIERDO N, de Yebenes VG, Alvarez-Prado AF, Mur SM, et al
    miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma.
    Blood. 2017 Feb 10. pii: blood-2016-08-731166. doi: 10.1182/blood-2016-08-731166
    PubMed     Text format     Abstract available


  121. NGUYEN HL, Kelley TW
    T-cell rosettes in nodular lymphocyte-predominant Hodgkin lymphoma.
    Blood. 2017;129:802.
    PubMed     Text format    


  122. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Text format     Abstract available


  123. NOY A, de Vos S, Thieblemont C, Martin P, et al
    Targeting BTK with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Blood. 2017 Feb 6. pii: blood-2016-10-747345. doi: 10.1182/blood-2016-10-747345.
    PubMed     Text format     Abstract available


    January 2017
  124. VAN NIMWEGEN FA, Ntentas G, Darby SC, Schaapveld M, et al
    Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
    Blood. 2017 Jan 31. pii: blood-2016-09-740332. doi: 10.1182/blood-2016-09-740332
    PubMed     Text format     Abstract available


  125. ABRAMSON JS
    Recurrent mutations and targeted therapy in FL.
    Blood. 2017;129:402-403.
    PubMed     Text format    


  126. BROCCOLI A, Zinzani PL
    Peripheral T-cell lymphoma, not otherwise specified.
    Blood. 2017 Jan 23. pii: blood-2016-08-692566. doi: 10.1182/blood-2016-08-692566
    PubMed     Text format     Abstract available


  127. LUNNING MA, Vose JM
    Angioimmunoblastic T-cell lymphoma: the many faced lymphoma.
    Blood. 2017 Jan 23. pii: blood-2016-09-692541. doi: 10.1182/blood-2016-09-692541
    PubMed     Text format     Abstract available


  128. GAYLE S, Landrette S, Beeharry N, Conrad C, et al
    Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
    Blood. 2017 Jan 19. pii: blood-2016-09-736892. doi: 10.1182/blood-2016-09-736892
    PubMed     Text format     Abstract available


  129. ALI ND, Weissmann D
    Charcot-Leyden crystals in T-cell lymphoblastic lymphoma.
    Blood. 2017;129:394.
    PubMed     Text format    


  130. SESQUES P, Johnson NA
    Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
    Blood. 2017;129:280-288.
    PubMed     Text format     Abstract available


  131. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available


  132. YAHALOM J
    Curative radiation for orbital MZL: how much?
    Blood. 2017;129:270-271.
    PubMed     Text format    


  133. ROSSI D, Diop F, Spaccarotella E, Monti S, et al
    Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
    Blood. 2017 Jan 17. pii: blood-2016-05-719641. doi: 10.1182/blood-2016-05-719641
    PubMed     Text format     Abstract available


  134. ZAHN M, Marienfeld R, Melzner I, Heinrich J, et al
    A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin's lymphoma cells.
    Blood. 2017 Jan 12. pii: blood-2016-06-720516. doi: 10.1182/blood-2016-06-720516
    PubMed     Text format     Abstract available


  135. KUO SH, Chen LT, Lin CW, Yeh KH, et al
    Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL.
    Blood. 2017;129:188-198.
    PubMed     Text format     Abstract available


  136. GANZEL C, Reinus C
    Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.
    Blood. 2017;129:268.
    PubMed     Text format    


  137. XU Z, Beaulieu Bergeron M
    Near-triploid B lymphoblastic leukemia with Burkitt-like morphology.
    Blood. 2017;129:267.
    PubMed     Text format    


  138. MERRYMAN RW, Kim HT, Zinzani PL, Carlo-Stella C, et al
    Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant After PD-1 Blockade in Relapsed/Refractory Lymphoma.
    Blood. 2017 Jan 10. pii: blood-2016-09-738385. doi: 10.1182/blood-2016-09-738385
    PubMed     Text format     Abstract available


  139. CURIEL-OLMO S, Mondejar R, Almaraz C, Mollejo M, et al
    Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin.
    Blood. 2017 Jan 9. pii: blood-2016-11-751024. doi: 10.1182/blood-2016-11-751024.
    PubMed     Text format    


  140. STEIDL C
    Exposing Hodgkin-Reed-Sternberg cells.
    Blood. 2017;129:6-7.
    PubMed     Text format    


    December 2016
  141. HUANG Q
    A striking bone marrow dyserythropoietic change but no anemia.
    Blood. 2016;128:3177.
    PubMed     Text format    


  142. LOGHAVI S, Medeiros LJ
    A rare histologic variant of a common lymphoma.
    Blood. 2016;128:3012.
    PubMed     Text format    


  143. FODERARO AE, Reagan JL
    Hodgkin lymphoma mimicking lung abscess.
    Blood. 2016;128:3011.
    PubMed     Text format    


  144. NISS ARFELT K, Barington L, Benned-Jensen T, Kubale V, et al
    EBI2 overexpression in mice leads to B1 B cell expansion and chronic lymphocytic leukemia-(CLL)-like B cell malignancies.
    Blood. 2016 Dec 21. pii: blood-2016-02-697185. doi: 10.1182/blood-2016-02-697185
    PubMed     Text format     Abstract available


  145. COHEN JB, Behera M, Thompson CA, Flowers CR, et al
    Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Blood. 2016 Dec 12. pii: blood-2016-08-685073.
    PubMed     Text format     Abstract available


    November 2016
  146. CONNORS JM
    Is the lymphoma better? Not easy to determine.
    Blood. 2016;128:2481-2482.
    PubMed     Text format    


  147. VILLA D
    Novel antivirals for HCV-associated lymphomas.
    Blood. 2016;128:2482-2483.
    PubMed     Text format    


  148. WERNER MT, Zhao C, Zhang Q, Wasik MA, et al
    Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK): the ultimate oncogene and therapeutic target.
    Blood. 2016 Nov 22. pii: blood-2016-05-717793.
    PubMed     Text format     Abstract available


  149. KIESEWETTER B, Willenbacher E, Willenbacher W, Egle A, et al
    A phase II study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
    Blood. 2016 Nov 22. pii: blood-2016-06-720599.
    PubMed     Text format     Abstract available


  150. DAI B, Grau M, Juilland M, Klener P, et al
    B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.
    Blood. 2016 Nov 18. pii: blood-2016-05-718775.
    PubMed     Text format     Abstract available


  151. WALTER R, Pan KT, Doebele C, Comoglio F, et al
    HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B cell receptor signaling.
    Blood. 2016 Nov 15. pii: blood-2016-06-721423. doi: 10.1182/blood-2016-06-721423
    PubMed     Text format     Abstract available


  152. KRYSIAK K, Gomez F, White BS, Matlock M, et al
    Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
    Blood. 2016 Nov 14. pii: blood-2016-07-729954. doi: 10.1182/blood-2016-07-729954
    PubMed     Text format     Abstract available


  153. NEFF JL, Chen D
    Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease.
    Blood. 2016;128:2275.
    PubMed     Text format    


  154. MATSUSHITA H, Maruyama D
    Bone marrow involvement of primary cutaneous gamma/delta T-cell lymphoma.
    Blood. 2016;128:2274.
    PubMed     Text format    


    October 2016
  155. DESAI A, Joag MG, Lekakis L, Chapman JR, et al
    Long term course of patients with primary ocular adnexal malt lymphoma: a large single institution cohort study.
    Blood. 2016 Oct 27. pii: blood-2016-05-714584.
    PubMed     Text format     Abstract available


  156. XU-MONETTE ZY, Li L, Byrd JC, Jabbar KJ, et al
    Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Blood. 2016 Oct 19. pii: blood-2016-05-715094.
    PubMed     Text format     Abstract available


  157. JACOBSON C, Kopp N, Layer JV, Redd RA, et al
    HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Blood. 2016 Oct 14. pii: blood-2016-04-711176.
    PubMed     Text format     Abstract available


  158. DU J, Neuenschwander M, Yu Y, Dabritz JH, et al
    Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma.
    Blood. 2016 Oct 12. pii: blood-2016-02-700773.
    PubMed     Text format     Abstract available


  159. CHIRON D, Bellanger C, Papin A, Tessoulin B, et al
    Microenvironment-dependent proliferation and mitochondrial priming loss in mantle cell lymphoma is overcome by anti-CD20.
    Blood. 2016 Oct 3. pii: blood-2016-06-720490.
    PubMed     Text format     Abstract available


  160. UJJANI CS, Jung SH, Pitcher B, Martin P, et al
    Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
    Blood. 2016 Oct 3. pii: blood-2016-06-718106.
    PubMed     Text format     Abstract available


    September 2016

  161. Sun B, Shah B, Fiskus W, et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015;126(13):1565-1574.
    Blood. 2016;128:1778.
    PubMed     Text format    


  162. MANSOURI L, Noerenberg D, Young E, Mylonas E, et al
    Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
    Blood. 2016 Sep 26. pii: blood-2016-03-704528.
    PubMed     Text format     Abstract available


  163. AMBINDER RF
    EBV, an inhibited receptor kinase, and lymphoma.
    Blood. 2016;128:1542-3.
    PubMed     Text format    


  164. OKAMURA I, Ikeda T
    Epstein-Barr virus associated with a lymphoma-mimicking lesion of the uterine cervix.
    Blood. 2016;128:1439.
    PubMed     Text format    


  165. ARCAINI L, Besson C, Frigeni M, Fontaine H, et al
    Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Blood. 2016 Sep 7. pii: blood-2016-05-714667.
    PubMed     Text format     Abstract available


  166. LIM MS
    Targetable gene fusions in T-cell lymphoma.
    Blood. 2016;128:1161-2.
    PubMed     Text format    


    August 2016
  167. CHESON BD, Ansell S, Schwartz L, Gordon LI, et al
    Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy.
    Blood. 2016 Aug 29. pii: blood-2016-05-718528.
    PubMed     Text format     Abstract available


  168. REZVANI AR
    A new standard for HIV-associated lymphoma.
    Blood. 2016;128:1026-7.
    PubMed     Text format    


    July 2016
  169. KUMAR A, Casulo C, Yahalom J, Schoder H, et al
    Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
    Blood. 2016 Jul 25. pii: blood-2016-03-703470.
    PubMed     Text format     Abstract available


  170. CHEN R, Gopal AK, Smith SE, Ansell SM, et al
    Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2016 Jul 18. pii: blood-2016-02-699850.
    PubMed     Text format     Abstract available


  171. JURINOVIC V, Kridel R, Staiger AM, Szczepanowski M, et al
    Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
    Blood. 2016 Jul 14. pii: blood-2016-05-717355.
    PubMed     Text format     Abstract available


  172. MIYOSHI H, Kiyasu J, Kato T, Yoshida N, et al
    PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Blood. 2016 Jul 14. pii: blood-2016-02-698936.
    PubMed     Text format     Abstract available


    June 2016
  173. MOIZ B, Majeed A
    Gray-zone lymphoma: a complex reality.
    Blood. 2016;127:3459.
    PubMed     Text format    


  174. ALBERTSSON-LINDBLAD A, Kolstad A, Laurell A, Raty R, et al
    Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4.
    Blood. 2016 Jun 27. pii: blood-2016-03-704023.
    PubMed     Text format     Abstract available


  175. HUANG YC, Lin SJ, Lin KM, Chou YC, et al
    Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.
    Blood. 2016 Jun 23. pii: blood-2016-02-702530.
    PubMed     Text format     Abstract available


  176. LYNCH DT, Foucar K
    Discrete vacuoles in lymphocytes as a subtle clue to mantle cell lymphoma.
    Blood. 2016;127:3292.
    PubMed     Text format    


  177. SPINA V, Khiabanian H, Messina M, Monti S, et al
    The genetics of nodal marginal zone lymphoma.
    Blood. 2016 Jun 22. pii: blood-2016-02-696757.
    PubMed     Text format     Abstract available


  178. LOUISSAINT A JR, Schafernak KT, Geyer J, Kovach AE, et al
    Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAP kinase pathway mutations.
    Blood. 2016 Jun 20. pii: blood-2015-12-682591.
    PubMed     Text format     Abstract available


  179. BHATTI R, Aguilera NS
    Reverse variant of follicular lymphoma: uncommon morphology in a common lymphoma.
    Blood. 2016;127:3103.
    PubMed     Text format    


  180. WANG HY, Wang L
    Diagnostic pitfall: primary effusion lymphoma with rare cytokeratin immunoreactivity.
    Blood. 2016;127:3102.
    PubMed     Text format    


  181. BODDICKER RL, Razidlo GL, Dasari S, Zeng Y, et al
    Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.
    Blood. 2016 Jun 13. pii: blood-2016-03-707141.
    PubMed     Text format     Abstract available


  182. ALVARNAS JC, Le Rademacher J, Wang Y, Little RF, et al
    Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the (BMT CTN) 0803/(AMC) 071 Trial.
    Blood. 2016 Jun 13. pii: blood-2015-08-664706.
    PubMed     Text format     Abstract available


  183. YAN J, Li B, Lin B, Lee PT, et al
    EZH2 phosphorylation by JAK3 mediates a switch to non-canonical function in natural killer/T-cell lymphoma.
    Blood. 2016 Jun 13. pii: blood-2016-01-690701.
    PubMed     Text format     Abstract available


  184. PRATT D, Uldrick TS
    Primary effusion lymphoma and concurrent progressive Kaposi sarcoma associated with elevated interleukin-6.
    Blood. 2016;127:2940.
    PubMed     Text format    


  185. DIAZ-CRESPO F, Mollejo M
    Intravascular large B-cell lymphoma in a kidney biopsy.
    Blood. 2016;127:2939.
    PubMed     Text format    


  186. SCHMIDT J, Gong S, Marafioti T, Mankel B, et al
    Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.
    Blood. 2016 Jun 2. pii: blood-2016-03-703819.
    PubMed     Text format     Abstract available


  187. CHEAH CY, Fowler NH
    Idelalisib in the management of lymphoma.
    Blood. 2016 Jun 1. pii: blood-2016-02-702761.
    PubMed     Text format     Abstract available


    May 2016
  188. CHESON BD
    Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
    Blood. 2016 May 24. pii: blood-2016-04-709477.
    PubMed     Text format     Abstract available


  189. KASENDA B, Loeffler J, Illerhaus G, Ferreri AJ, et al
    The role of whole brain radiation in primary CNS lymphoma.
    Blood. 2016 May 13. pii: blood-2016-01-650101.
    PubMed     Text format     Abstract available


  190. ASSOULINE SE, Nielsen TH, Yu S, Alcaide M, et al
    Phase 2 study of panobinostat +/- rituximab in relapsed diffuse large B cell lymphoma and biomarkers predictive of response.
    Blood. 2016 May 10. pii: blood-2016-02-699520.
    PubMed     Text format     Abstract available


  191. MATTHEWS JM, Bhatt S, Patricelli MP, Nomanbhoy TK, et al
    Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.
    Blood. 2016 May 5. pii: blood-2016-02-696856.
    PubMed     Text format     Abstract available


    April 2016
  192. SABA NS, Liu D, Herman SE, Underbayev C, et al
    Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma.
    Blood. 2016 Apr 28. pii: blood-2015-11-681460.
    PubMed     Text format     Abstract available


  193. KOTSIOU E, Okosun J, Besley C, Iqbal S, et al
    TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.
    Blood. 2016 Apr 21. pii: blood-2015-10-679191.
    PubMed     Text format     Abstract available


  194. LI W, Repnikova E
    ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis.
    Blood. 2016;127:2041.
    PubMed     Text format    


  195. FANALE M
    New insights into NLPHL transformation.
    Blood. 2016;127:1946-7.
    PubMed     Text format    


  196. ROSCHEWSKI M, Staudt LM, Wilson WH
    Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.
    Blood. 2016 Apr 14. pii: blood-2016-03-635219.
    PubMed     Text format     Abstract available



  197. McFarland W, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood. 1959;14(5):503-521.
    Blood. 2016;127:1839.
    PubMed     Text format     Abstract available


  198. BLONSKA M
    ATF3, a new player in DLBCL cell survival.
    Blood. 2016;127:1736-7.
    PubMed     Text format     Abstract available


  199. JUILLAND M, Gonzalez M, Erdmann T, Banz Y, et al
    CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
    Blood. 2016;127:1780-9.
    PubMed     Text format     Abstract available


  200. KNITTEL G, Liedgens P, Korovkina D, Seeger JM, et al
    B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice.
    Blood. 2016 Apr 5. pii: blood-2015-11-684183.
    PubMed     Text format     Abstract available


    March 2016
  201. ZIJLSTRA JM
    PET-CT: reliable cornerstone for Hodgkin lymphoma treatment?
    Blood. 2016;127:1521-2.
    PubMed     Text format    


  202. PAGANO JS, Shackelford J
    UCH-L1 in DLBCL: marker or target?
    Blood. 2016;127:1524-5.
    PubMed     Text format     Abstract available


  203. SMITH MR
    Ibrutinib: a force with a dark side?
    Blood. 2016;127:1523-4.
    PubMed     Text format     Abstract available


  204. ARMITAGE JO, Longo DL
    Is watch and wait still acceptable for patients with low grade follicular lymphoma?
    Blood. 2016 Mar 18. pii: blood-2015-11-632745.
    PubMed     Text format     Abstract available


  205. ARCAINI L, Rossi D, Paulli M
    Splenic marginal zone lymphoma: from genetics to management.
    Blood. 2016 Mar 17. pii: blood-2015-11-624312.
    PubMed     Text format     Abstract available


  206. KURUVILLA J
    The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.
    Blood. 2016 Mar 17. pii: blood-2015-11-624320.
    PubMed     Text format     Abstract available


  207. ZUCCA E, Bertoni F
    The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance.
    Blood. 2016 Mar 17. pii: blood-2015-12-624304.
    PubMed     Text format     Abstract available


  208. KAHL BS, Yang D
    Follicular lymphoma: evolving therapeutic strategies.
    Blood. 2016 Mar 17. pii: blood-2015-11-624288.
    PubMed     Text format     Abstract available


  209. THIEBLEMONT C, Molina T, Davi F
    Optimizing therapy for nodal marginal zone lymphoma.
    Blood. 2016 Mar 17. pii: blood-2015-12-624296.
    PubMed     Text format     Abstract available


  210. HEALY JA, Nugent A, Rempel RE, Moffitt AB, et al
    GNA13 loss in germinal center B cells leads to impaired apoptosis and GC B cell persistence and promotes lymphoma in vivo.
    Blood. 2016 Mar 17. pii: blood-2015-07-659938.
    PubMed     Text format     Abstract available


  211. MASKOVYAK AE, Nakashima MO
    Circulating CD30-positive T-cell lymphoma with anaplastic morphology.
    Blood. 2016;127:1516.
    PubMed     Text format    


  212. BALDARI CT
    S1PR2 deficiency in DLBCL: a FOXy connection.
    Blood. 2016;127:1380-1.
    PubMed     Text format     Abstract available


  213. CHOUDHARI R, Minero VG, Menotti M, Pulito R, et al
    Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.
    Blood. 2016;127:1297-306.
    PubMed     Text format     Abstract available


  214. KOZLOSKI GA, Jiang X, Bhatt S, Ruiz J, et al
    MiR-181a negatively regulates NF-kappaB signaling and affects activated B-cell like diffuse large B-cell lymphoma pathogenesis.
    Blood. 2016 Mar 3. pii: blood-2015-11-680462.
    PubMed     Text format     Abstract available


    February 2016
  215. CHEN Z, Hu S
    MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation.
    Blood. 2016;127:1072.
    PubMed     Text format    


  216. YEOMANS A, Packham G
    Shooting the messenger (RNA) in B-cell lymphoma.
    Blood. 2016;127:794-6.
    PubMed     Text format    


  217. DUROT E, Patey M
    Pure red cell aplasia revealing nonnodal mantle cell lymphoma.
    Blood. 2016;127:952.
    PubMed     Text format    


  218. KANAKRY JA, Luznik L
    Might haplo "be the (better) match"?
    Blood. 2016;127:799-800.
    PubMed     Text format    


  219. CHAPUY B, Roemer MG, Stewart C, Tan Y, et al
    Targetable genetic features of primary testicular and primary central nervous system lymphomas.
    Blood. 2016;127:869-81.
    PubMed     Text format     Abstract available


  220. KANATE AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, et al
    Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
    Blood. 2016;127:938-47.
    PubMed     Text format     Abstract available


  221. CULJKOVIC-KRALJACIC B, Fernando TM, Marullo R, Calvo-Vidal N, et al
    Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
    Blood. 2016;127:858-68.
    PubMed     Text format     Abstract available


  222. LYKKEN JM, Horikawa M, Minard-Colin V, Kamata M, et al
    Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms.
    Blood. 2016 Feb 17. pii: blood-2015-11-681130.
    PubMed     Text format     Abstract available


  223. SZYDLOWSKI M, Kiliszek P, Sewastianik T, Jablonska E, et al
    FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Blood. 2016;127:739-48.
    PubMed     Text format     Abstract available


  224. EFREMOV DG
    FOXO discriminates tonic from chronic in DLBCL.
    Blood. 2016;127:669-70.
    PubMed     Text format    


  225. KENDERIAN SS, Habermann TM, Macon WR, Ristow KM, et al
    Large B-cell transformation in nodular lymphocyte predominant Hodgkin lymphoma: forty-year experience from a single institution.
    Blood. 2016 Feb 2. pii: blood-2015-08-665505.
    PubMed     Text format     Abstract available


  226. FERRERI AJ, Illerhaus G
    The role of autologous stem cell transplantation in primary CNS lymphoma.
    Blood. 2016 Feb 1. pii: blood-2015-10-636340.
    PubMed     Text format     Abstract available


  227. BOLL B, Goergen H, Behringer K, Brockelmann PJ, et al
    Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
    Blood. 2016 Feb 1. pii: blood-2015-11-681064.
    PubMed     Text format     Abstract available


    January 2016
  228. WALTER HS, Rule SA, Dyer MJ, Karlin L, et al
    A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
    Blood. 2016;127:411-9.
    PubMed     Text format     Abstract available


  229. CHAPUY B, Cheng H, Watahiki A, Ducar MD, et al
    Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biologic heterogeneity of the disease.
    Blood. 2016 Jan 15. pii: blood-2015-09-672352.
    PubMed     Text format     Abstract available


  230. MIRANTES C, Dosil MA, Hills D, Yang J, et al
    Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma, but not myeloid malignancies.
    Blood. 2016 Jan 14. pii: blood-2015-09-669036.
    PubMed     Text format     Abstract available


  231. GAULARD P, de Leval L
    ALK-negative anaplastic large-cell lymphoma.
    Blood. 2016;127:175-7.
    PubMed     Text format    


  232. ARNOUX I, Loosveld M
    Hepatosplenic T-cell lymphoma: an acute leukemia presentation.
    Blood. 2016;127:269.
    PubMed     Text format    


  233. KING RL, Howard MT
    Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman.
    Blood. 2016;127:268.
    PubMed     Text format    


  234. SCARFO I, Pellegrino E, Mereu E, Kwee I, et al
    Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.
    Blood. 2016;127:221-32.
    PubMed     Text format     Abstract available


  235. DOLCETTI R, Gloghini A, Caruso A, Carbone A, et al
    A lymphomagenic role for HIV beyond immune suppression?
    Blood. 2016 Jan 14. pii: blood-2015-11-681411.
    PubMed     Text format     Abstract available


  236. MARTIN P, Maddocks K, Leonard JP, Ruan J, et al
    Post-ibrutinib outcomes in patients with mantle cell lymphoma.
    Blood. 2016 Jan 13. pii: blood-2015-10-673145.
    PubMed     Text format     Abstract available


  237. VIARDOT A, Goebeler ME, Hess G, Neumann S, et al
    Phase 2 study of bispecific T-cell engager (BiTE(R)) antibody blinatumomab in relapsed/refractory diffuse large B cell lymphoma.
    Blood. 2016 Jan 11. pii: blood-2015-06-651380.
    PubMed     Text format     Abstract available


  238. JAIN N, Lamb AE, O'Brien S, Ravandi F, et al
    Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.
    Blood. 2016 Jan 8. pii: blood-2015-08-661702.
    PubMed     Text format     Abstract available


  239. BARRINGTON SF, Kirkwood AA, Franceschetto A, Fulham MJ, et al
    PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033).
    Blood. 2016 Jan 8. pii: blood-2015-11-679407.
    PubMed     Text format     Abstract available


  240. FLOWERS CR, Skibola CF
    Identifying risk factors for B-cell lymphoma.
    Blood. 2016;127:10-1.
    PubMed     Text format    


  241. WILLERSLEV-OLSEN A, Krejsgaard T, Lindahl LM, Litvinov IV, et al
    Staphylococcus aureus enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
    Blood. 2016 Jan 5. pii: blood-2015-08-662353.
    PubMed     Text format     Abstract available


  242. FLORI M, Schmid CA, Sumrall ET, Tzankov A, et al
    The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
    Blood. 2016 Jan 4. pii: blood-2015-08-662635.
    PubMed     Text format     Abstract available


    December 2015
  243. RADFORD J
    Treatment of Hodgkin lymphoma in older patients.
    Blood. 2015;126:2768-9.
    PubMed     Text format    


  244. BEDEKOVICS T, Hussain S, Feldman AL, Galardy PJ, et al
    UCH-L1 is induced in germinal center B-cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Blood. 2015 Dec 23. pii: blood-2015-07-656678.
    PubMed     Text format     Abstract available


  245. BRUDNO J, Tadmor T, Pittaluga S, Nicolae A, et al
    Discordant bone marrow involvement in non-Hodgkin lymphoma.
    Blood. 2015 Dec 17. pii: blood-2015-06-651968.
    PubMed     Text format     Abstract available


  246. CZUCZMAN NM, Barth MJ, Gu J, Neppalli V, et al
    Pevonedistat, a NEDD8 activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Blood. 2015 Dec 16. pii: blood-2015-04-640920.
    PubMed     Text format     Abstract available


    November 2015
  247. CHOI SM, Chen YH
    Primary effusion lymphoma.
    Blood. 2015;126:2522.
    PubMed     Text format    


  248. COPIE-BERGMAN C, Cuilliere-Dartigues P, Baia M, Briere J, et al
    MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
    Blood. 2015;126:2466-74.
    PubMed     Text format     Abstract available


  249. CAMPO E
    MYC in DLBCL: partners matter.
    Blood. 2015;126:2439-40.
    PubMed     Text format     Abstract available


  250. AGARWAL NK, Kim CH, Kunkalla K, Konno H, et al
    Active IKKbeta promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma.
    Blood. 2015 Nov 24. pii: blood-2015-07-658781.
    PubMed     Text format     Abstract available


  251. MATTHEWS GM, Mehdipour P, Cluse LA, Falkenberg KJ, et al
    Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
    Blood. 2015;126:2392-403.
    PubMed     Text format     Abstract available


  252. KELLY KM
    Hodgkin lymphoma in children and adolescents: improving the therapeutic index.
    Blood. 2015 Nov 18. pii: blood-2015-07-641035.
    PubMed     Text format     Abstract available


  253. ALINARI L, Blum KA
    How I treat relapsed classical Hodgkin Lymphoma after autologous stem cell transplant.
    Blood. 2015 Nov 17. pii: blood-2015-10-671826.
    PubMed     Text format     Abstract available


  254. NAGATA Y, Kontani K, Enami T, Kataoka K, et al
    Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
    Blood. 2015 Nov 16. pii: blood-2015-06-644948.
    PubMed     Text format     Abstract available


  255. ARANGO M
    Adult T-cell leukemia/lymphoma.
    Blood. 2015;126:2343.
    PubMed     Text format    


  256. BENEDICT M, Hudnall D
    Lymphoplasmacytic lymphoma with prominent mast cell infiltrates.
    Blood. 2015;126:2342.
    PubMed     Text format    


  257. HATHCOCK KS, Padilla-Nash HM, Camps J, Shin DM, et al
    ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.
    Blood. 2015;126:2291-301.
    PubMed     Text format     Abstract available


  258. DIERICKX D, Tousseyn T, Gheysens O
    How I treat posttransplant lymphoproliferative disorders.
    Blood. 2015;126:2274-83.
    PubMed     Text format     Abstract available


  259. BOUSSIOTIS VA
    Cell-specific PD-L1 expression in DLBCL.
    Blood. 2015;126:2171-2.
    PubMed     Text format    


    October 2015
  260. BENAYOUN E, Wagner-Ballon O
    Hepatosplenic T-cell lymphoma mimicking bone marrow metastasis.
    Blood. 2015;126:2071.
    PubMed     Text format    


  261. DEBORD C, Eveillard M
    Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease.
    Blood. 2015;126:1966.
    PubMed     Text format    


  262. OFFNER F, Samoilova O, Osmanov E, Eom HS, et al
    Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
    Blood. 2015;126:1893-901.
    PubMed     Text format     Abstract available


  263. KHAN N, Fisher RI
    Subtype-specific therapy for DLBCL: are we there yet?
    Blood. 2015;126:1869-70.
    PubMed     Text format     Abstract available


  264. WANG HY, Thorson JA
    T-cell primary effusion lymphoma with pseudo-monoclonal rearrangements for immunoglobulin heavy chain.
    Blood. 2015;126:1856.
    PubMed     Text format    


  265. PILERI SA
    Follicular helper T-cell-related lymphomas.
    Blood. 2015;126:1733-4.
    PubMed     Text format     Abstract available


  266. MARTIN P
    Is the open mouth mightier than the needle?
    Blood. 2015;126:1638-9.
    PubMed     Text format     Abstract available


  267. LU Z, Pannunzio NR, Greisman HA, Casero D, et al
    Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations.
    Blood. 2015;126:1730-1.
    PubMed     Text format    


    September 2015
  268. KUMAR A, Puvvada S
    Mantle cell lymphoma presenting as cardiac tamponade.
    Blood. 2015;126:1255.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: